
KNSA Stock Forecast & Price Target
KNSA Analyst Ratings
Bulls say
Kiniksa Pharmaceuticals has demonstrated a robust financial trajectory, achieving 2024 Arcalyst revenue of $417 million, which reflects a remarkable 79% year-over-year increase and surpasses initial management guidance. This significant revenue growth has been attributed to an expanding prescriber base, which rose to over 2,850 unique prescribers by 4Q24, marking a steady increase from prior quarters. Additionally, the average duration of Arcalyst therapy in recurrent pericarditis has also improved, rising to approximately 27 months in 4Q24 from 23 months in 1Q24, signaling enhanced treatment effectiveness and patient retention.
Bears say
Kiniksa Pharmaceuticals faces significant challenges due to potential competition from superior products, which could negatively impact its market position and pricing power. Additionally, the adoption of their product Arcalyst for recurrent pericarditis may fall short of expectations, further jeopardizing revenue potential. These factors, combined with regulatory and commercial risks associated with pricing in the rare disease segment, contribute to a negative outlook for the company's stock.
This aggregate rating is based on analysts' research of Kiniksa Pharmaceuticals Ltd and is not a guaranteed prediction by Public.com or investment advice.
KNSA Analyst Forecast & Price Prediction
Start investing in KNSA
Order type
Buy in
Order amount
Est. shares
0 shares